scispace - formally typeset
D

Diren Beyoğlu

Researcher at Long Island University

Publications -  39
Citations -  1238

Diren Beyoğlu is an academic researcher from Long Island University. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 15, co-authored 30 publications receiving 967 citations. Previous affiliations of Diren Beyoğlu include University of Bern & Marmara University.

Papers
More filters
Journal ArticleDOI

Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling.

TL;DR: The findings of a plasma metabolomic investigation of HCC patients by ultraperformance liquid chromatography-electrospray ionization-quadrupole time-of-flight mass spectrometry (UPLC-ESI-QTOFMS), random forests machine learning algorithm, and multivariate data analysis found that HCC was associated with increased plasma levels of glycodeoxycholate, de oxygencholate 3-sulfate, and bilirubin.
Journal ArticleDOI

The metabolomic window into hepatobiliary disease

TL;DR: The metabolomic window into hepatobiliary disease sheds new light on the systems pathology of the liver.
Journal ArticleDOI

Tissue metabolomics of hepatocellular carcinoma: Tumor energy metabolism and the role of transcriptomic classification†‡

TL;DR: Tissue metabolomics yielded precise biochemical information regarding HCC tumor metabolic remodeling from mitochondrial oxidation to aerobic glycolysis and the impact of molecular subtypes on this process.
Journal ArticleDOI

Potential role of CYP2D6 in the central nervous system.

TL;DR: The Tg-2D6 mouse model may serve as a valuable in vivo tool to determine CYP2D 6-involved neurophysiological metabolism and function, and anxiety tests indicate T g- 2D6 mice have a higher capability to adapt to anxiety.
Journal ArticleDOI

Metabolomics and its potential in drug development.

TL;DR: Although not yet established as a clinical trial patient prescreening procedure, metabolomics shows considerable promise in this regard and can be certain that metabolomics will join genomics and transcriptomics in lubricating the wheels of clinical drug development in the near future.